本帖最后由 老马 于 2012-1-13 21:20 编辑
% z" G9 L9 s5 Q4 a, v) W# {" T4 | M# d& e
爱必妥和阿瓦斯丁的比较
7 \9 C2 O3 f1 f$ U: [1 l& e. n
9 Y( D6 P8 ], B6 jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 a, k$ o5 n' W
$ C: l. W/ z! B7 c7 O$ r) D2 o
' _$ }0 n% G0 X8 Y+ ahttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. H' `. C* f5 s; h8 \1 U; c0 U
==================================================" |6 B! c" [8 e, p- z) ], n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: t* B0 X# \+ X( ^) T/ UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: S! ^2 }7 ]! G9 B6 x4 P; `7 X) oResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* n0 Z+ [7 o! X. Z# ^* _
|